Drugs / CD19-UCART
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05381181 | Dec 2023 → May 2024 | acute lymphoblastic leukemia | Bioray Laboratories | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT03229876 | Jun 2019 → Dec 2023 | acute lymphoblastic leukemia | Bioray Laboratories | Suspended | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19-UCART | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05381181 ↗ |
| Modality | Cell therapy | “Allogeneic Engineered T-cells Expressing Anti-CD19 Chimeric Antigen Receptor” NCT03229876 ↗ |
| Target | CD19 | “Allogeneic Engineered T-cells Expressing Anti-CD19 Chimeric Antigen Receptor” NCT03229876 ↗ |